https://astx.com/wp-content/uploads/2019/11/logo_white.png00webadminhttps://astx.com/wp-content/uploads/2019/11/logo_white.pngwebadmin2012-11-25 15:21:032016-11-25 15:21:392012 EORTC: Activity of the HSP90 inhibitor AT13387 in ALK-driven tumor models
https://astx.com/wp-content/uploads/2019/11/logo_white.png00webadminhttps://astx.com/wp-content/uploads/2019/11/logo_white.pngwebadmin2012-09-25 15:21:552016-11-25 15:22:222012 ASCO:FIH phase I study-results of HSP90 inhibitor AT13387 in refractory solid tumors
https://astx.com/wp-content/uploads/2019/11/logo_white.png00webadminhttps://astx.com/wp-content/uploads/2019/11/logo_white.pngwebadmin2012-07-25 15:22:442016-11-25 15:23:152012 ASCO: Phase I Study Assessing QDx2 schedule of AT13387 in Advanced Solid Tumors
https://astx.com/wp-content/uploads/2019/11/logo_white.png00webadminhttps://astx.com/wp-content/uploads/2019/11/logo_white.pngwebadmin2012-05-25 15:23:292016-11-25 15:23:552012 AACR: AT13387, HSP90 inhibitor effective in vemurafenib-sensitive and -resistant melanoma model
